BACE1 and Alzheimer disease: LR- or MAM-bound palAPP is considered a potential therapeutic target for AD because it serves as a preferential substrate for BACE1, the rate limiting step for Aβ generation in vitro and in vivo (reviewed in Wlodarczyk et al., 2024).